A Phase II trial of gemcitabine for metastatic neuroendocrine tumors
Open Access
- 18 August 2004
- Vol. 101 (5), 934-939
- https://doi.org/10.1002/cncr.20466
Abstract
BACKGROUND Treatment with traditional cytotoxic chemotherapy regimens containing streptozocin or dacarbazine has resulted in only marginal benefit for patients with metastatic neuroendocrine tumors. The use of these regimens has been further limited by their potential toxicity. Gemcitabine is generally well tolerated and possesses demonstrated activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine in the treatment of patients with metastatic neuroendocrine tumors. METHODS Eighteen patients with metastatic neuroendocrine tumors were treated with gemcitabine administered on a standard weekly schedule. Patients were followed for evidence of toxicity, response, and survival. RESULTS Gemcitabine was well tolerated. However, no radiologic or biochemical responses were observed. Although the majority of patients (65%) experienced disease stabilization as their best response to therapy, the overall median survival duration was only 11.5 months. CONCLUSIONS The minimal activity of gemcitabine highlighted the need for novel treatment approaches. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 16 references indexed in Scilit:
- Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study GroupJournal of Clinical Oncology, 2003
- Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumoursAnnals of Oncology, 2002
- Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282Annals of Oncology, 2001
- A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumorsCancer, 2001
- Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1992
- The Role of Interferons in the Management of Carcinoid TumorsActa Oncologica, 1991
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Malignant Pheochromocytoma: Effective Treatment with a Combination of Cyclophosphamide, Vincristine, and DacarbazineAnnals of Internal Medicine, 1988
- Treatment of metastatic pheochromocytoma with streptozocinArchives of Internal Medicine, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958